logo

DermNet NZ

Ad

Facts about the skin from DermNet New Zealand Trust. Topic index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Incontinentia pigmenti

Incontinentia pigmenti is also referred to as ‘Bloch-Sulzberger syndrome’, ‘Bloch-Siemens syndrome’, ‘melanoblastosis cutis linearis’, and ‘pigmented dermatosis-Siemens-Bloch type’.

What is incontinentia pigmenti?

Incontinentia pigmenti is a rare genetic condition characterised by skin, eye, teeth and central nervous system (CNS) abnormalities. The characteristic skin lesions of incontinentia pigmenti are present at birth or develop in the first few weeks of life in approximately 90% of patients.

What causes incontinentia pigmenti?

Incontinentia pigmenti is a dominant X-linked disease. This means that the abnormal incontinentia pigmenti gene is located on one of the X chromosomes, which determine the sex of a child (XY=male; XX=female). Dominant X-linked disease means that a female with only one copy of the abnormal gene will show the disease, even though they have a normal gene on their other X-chromosome. Males who inherit the abnormal gene do not survive, resulting in miscarriage or stillbirth (X-linked dominant, male lethal syndrome). Rarely incontinentia pigmenti is reported in males with Klinefelter syndrome (XXY syndrome) or as a result of spontaneous mutations.

The incontinentia pigmenti gene is localised on chromosome Xq28. This gene normally codes for the nuclear factor-KB essential modulator protein (the NEMO or NF-kappaB gene).

What are the cutaneous features of incontinentia pigmenti?

Progressive skin rashes are the main clinical feature of the disease. There are four recognised clinical stages but their sequence is irregular, their duration variable and they may overlap.

Stage 1: Vesicular
  • Most often affects extremities and scalp but can arise on any part of body
  • Red, blister-like lesions
  • Often appear grouped in lines along the arms and legs (following so-called lines of Blaschko)
  • Present at birth or within the first 2 weeks of life in 90% of patients
  • May last from a few weeks to a few months and recur throughout the first few months of life
Stage 2: Verrucous
  • Wart-like or pustular lesions
  • Thick crusts or scabs form over healing blisters
  • Lesions may be darker in skin colour (hyperpigmentation)
  • May be present at birth but in 70-80% of patients evolves after the first stage
  • May last for months, but rarely longer than a year
Stage 3: Hyperpigmented
  • Skin is darkened in a swirled pattern
  • Pigmentation ranges from blue-grey or slate to brown
  • Present at birth in 5-10% of patients but usually appears within the first few months of life in 90-98% of patients
  • Darkened patches may or may not be related to areas affected in stage 1 and 2
  • Heavy pigmentation tends to fade slowly with increasing age
Stage 4: Atrophic/ hypopigmented
  • Scar-like lesions develop during adolescence and persist into adulthood
  • Occur in 30-75% of patients
  • Appear as pale, hairless patches or streaks
Incontinentia pigmenti
Vesicular stage of incontinentia pigmenti

Other organ involvement

Other organs may be affected in various ways in patients with incontinentia pigmenti. These manifestations may not be seen or recognised until infancy or early childhood.

Teeth
  • Abnormalities in more than 80% of patients
  • Delay in eruption of teeth (both baby and adult teeth affected)
  • Some teeth may be missing altogether
  • Teeth may be unusually shaped, typically pegged or cone-shaped
Nails
  • May be involved in up to 40% of patients
  • Nails may be ridged, pitted, thickened or completely disfigured
  • Usually all or multiple finger and toe nails are affected
Hair
  • Minor hair abnormalities in up to 50% of patients
  • Loss or lack of hair on the crown of the head
  • Absence of eyebrows and eyelashes
  • Hair may be coarse, wiry and lack lustre
Eyes
  • Eye defects occur in 20-35% of patients
  • Typically occur before age 5
  • Disease causes an abnormality in the growth of blood vessels in the inside of the eye resulting in scarring
  • Can cause blindness but may be treated if recognised early enough
Central Nervous System
  • Neurological complications may occur in up to 30% of patients
  • Most common complication is seizures which usually develop within the first few weeks of life
  • Other manifestations include slow motor development, mental retardation, spastic paralysis, cerebral atrophy

What is the treatment for incontinentia pigmenti?

There is no specific treatment for incontinentia pigmenti. The main goal is to prevent secondary bacterial infection of skin lesions and to monitor closely the development of related problems. This should include regular dental care and close monitoring by an ophthalmologist for the first few years of life.

Related information

References:

On DermNet NZ:

Other websites:

Books about skin diseases:

See the DermNet NZ bookstore

Author: Vanessa Ngan, staff writer

DermNet NZ does not provide an on-line consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.